Metformin, placebo, and endocrine therapy discontinuation among participants in a randomized double-blind trial of metformin vs placebo in hormone receptor-positive early-stage breast cancer (CCTG MA32).
Dawn L HershmanBingshu E ChenClaire SatheWendy R ParulekarJulie LemieuxJennifer A LigibelKaren A GelmonTimothy J WhelanPamela J GoodwinPublished in: Breast cancer research and treatment (2023)
ClinicalTrials.gov: NCT01.